The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
about
Trial Watch: Peptide-based anticancer vaccines.Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Immunotherapy biomarkers 2016: overcoming the barriers.Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.Novel avenues in immunotherapies for colorectal cancer.Current status and future prospects of peptide-based cancer vaccines.The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice.Immunotherapy of colorectal cancer: new perspectives after a long path.Emerging trends in the immunotherapy of pancreatic cancer.Current Strategies to Enhance Anti-Tumour Immunity.Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration.
P2860
Q34483345-332859BF-1DC5-4372-AB8E-5ACDD51258C9Q35718060-0353B2A8-98CC-4EA9-AC6A-AB79D7A4239AQ36021163-F13D6A65-45FE-4238-80E9-99B7DE96C67DQ36643027-EBC814A0-9122-43CC-9008-E1150A0516D2Q37013898-39EAA30A-7452-4690-9DEB-38A0453E6C95Q37224581-7A0508B2-AC06-47FE-A97B-658F98731E6BQ37713438-45F245CB-1C34-4E7A-AFC8-6794337343DAQ38357201-1B69AF21-DED0-4E77-8782-E193ACBB8340Q38637906-28044687-93A5-4754-92CF-1D40AD03417BQ38780728-1FF504FA-F7F5-4C9F-A683-2C207EF0D195Q38973146-5C244BC0-A955-4AE3-AD6C-FE0E4E17787AQ39043413-9A9ABD7C-B422-4720-8C2D-331B5E54BF85Q47248817-224701B7-DD89-4AF4-800E-9C0BAA9A7F6AQ52344613-2FE7B990-E88B-4F52-A9CE-80FE176CFCB6Q54974100-745BF7CD-3560-4FA8-96B1-29C76D0A603AQ55003766-D250B405-D371-4A08-9FB4-DFC63B47B9D8
P2860
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The immunological and clinical ...... in patients with solid tumors.
@ast
The immunological and clinical ...... in patients with solid tumors.
@en
type
label
The immunological and clinical ...... in patients with solid tumors.
@ast
The immunological and clinical ...... in patients with solid tumors.
@en
prefLabel
The immunological and clinical ...... in patients with solid tumors.
@ast
The immunological and clinical ...... in patients with solid tumors.
@en
P2093
P2860
P356
P1476
The immunological and clinical ...... in patients with solid tumors.
@en
P2093
David J Liewehr
J Michael Hamilton
Malgorzata Wojtowicz
Omar Dakheel
Osama E Rahma
Samir N Khleif
Sarah Bernstein
Seth M Steinberg
P2860
P2888
P356
10.1186/1479-5876-12-55
P577
2014-02-24T00:00:00Z
P5875
P6179
1012941108